



BioMILD & SMILE trials

Ugo Pastorino Thoracic Surgery, Istituto Nazionale Tumori of Milan, Italy

DISCLOSURES

- no commercial interest
- microRNA signature classifiers patent (not on the market)

INTM screening strategy: target individual risk

baseline LDCT - longer screening intervals

non invasive ADC active surveillance of SSNs

different biologic risk blood miRNA signature




anti-tobacco therapy

Pastorino, INTM, Italy

MILD screening intervals






Ann Oncol 2019; 30:1672 Eur J Cancer 2019; 118:142-8 WCLC 2019, Barcelona, Abstract # 907; clinicaltrials.gov ID: NCT02247453




JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT




Eur J Cancer. 2019;118:142

blood microRNA for LDCT screening development of a signature classifier (MSC)



Boeri et al. PNAS, 2011; Sozzi et al. JCO, 2014

origin of the 24 INTM blood microRNAs




less than 20% from LC cells

Sestini S. Oncotarget 2015;

Fortunato O. Int J Cancer 2019


MILD vs. BioMILD screening intervals



Ann Oncol 2019; 30:1672 Eur J Cancer 2019; 118:142-8 WCLC 2019, Barcelona, Abstract # 907; clinicaltrials.gov ID: NCT02247453 IASLC ((1000) 2020 World Conference

JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT

Baseline volumetric LDCT cut-off intervals



Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy




clinicaltrials.gov ID: NCT02247453

BioMILD trial: AIMS

 evaluate the utility of blood microRNA and LDCT for prediction of individual LC risk



- assess the feasibility and safety of 3-year screening interval in subjects with double negative baseline LDCT and microRNA
- reveal potential damage of 3-year LDCT interval: stage I LC, resection rates, interval cancer




Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy



2019 World Conference on Lung Cancer September 7–10, 2019 | Barcelona, Spain

Lung cancer incidence




Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

clinicaltrials.gov ID: NCT02247453

wclc2019.iaslc.com

Conquering Thoracic Cancers Worldwide

#WCLC19



Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy



2019 World Conference on Lung Cancer September 7–10, 2019 | Barcelona, Spain

Conquering Thoracic Cancers Worldwide

Active surveillance of subsolid nodules (225 subjects)


Milientie Inline Inter Deterior Preese edit Innee poinnare	Subsolid nodules (<u>SSNs</u>)	2neg 33*	1pos 135	2pos 57	
	SSN % at baseline	1.4%	8.8%	27.3%	5.4%
	LC from SSN	0	7	0	3%
	LC deaths from SSN	0	0	0	

no LC deaths from SSN site

Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

* SSN < 5 mm

surgical outcome by screening intervals



Ugo Pastorino, Istituto Nazionale dei Tumori, Milan, Italy



2020 World Conference on Lung Cancer Singapore

JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT

BioMILD results: April 2021 update



- median follow-up of 5.3 years
- safety of 3-year interval for LDCT- / MSC-
- no increase of high stage or unresectable LC
- risk prediction confirmed at 5 years




- added value of miRNA on LCRAT and PLCOm2012
- final results have been submitted for publication






ultra-low-dose LDCT Screening and Multiple Intervention on Lung Epidemics

Population: 55-75 yrs-old current / ex-smokers ≥ 30 pack / years



2 x 2 factorial design



clinicaltrials.gov ID: NCT03654105

Pastorino, INTM, Italy



natural origin (Cytisus laburnum)

• used in Est Europa since 1960

Citisine

- partial agonist of α4β2 nicotine receptors
- excellent tolerability

clinicaltrials.gov ID: NCT03654105

Pastorino, INTM, Italy



> 30% CO-confirmed quitters at 12 months

primary end-points

citisine



> 30% decrease of blood CRP at 24 months

cardioASA + diet + exercise

Pastorino, INTM, Italy



- LDCT screening started in July 2019
- of 2,000 planned subjects, 1114 were randomised
- accrual was stopped in March 2020 due to Covid-19
- 978 subjects had received baseline LDCT
- study re-started in October 2020 with swab protection
- 739 (76%) received 12-months LDCT control
- Citisine efficacy analysis is planned by September 2021

Pastorino, INTM, Italy


clinicaltrials.gov ID: NCT03654105

Trial status Smile Smile

FEASIBILITY AND SAFETY OF LUNG CANCER SCREENING AND PREVENTION DURING COVID-19 PANDEMIC

SARS-COV-2 ANTIGEN RAPID TEST CE IVD

Lateral flow immunochromatographic assay for the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.



Milanese G. Chest 2021, https://doi.org/10.1016/j.chest.2021.02.072





BioMILD & SMILE: take home message

- targeted screening intervals after baseline are safe
- overtreatment can be limited by SSNs surveillance
- LDCT + prevention is feasible to reduce all-cause mortality
- added value of miRNA assay is ready to be tested by RCT
- LDCT screening was feasible during **Covid-19** pandemic

Pastorino, INTM, Italy